Your browser doesn't support javascript.
loading
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.
Lickliter, Jason D; Voskoboynik, Mark; Mileshkin, Linda; Gan, Hui K; Kichenadasse, Ganessan; Zhang, Kathy; Zhang, Maggie; Tang, Zhiyu; Millward, Michael.
Affiliation
  • Lickliter JD; Nucleus Network, Melbourne, VIC, Australia.
  • Voskoboynik M; Nucleus Network, Melbourne, VIC, Australia.
  • Mileshkin L; Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Gan HK; Peter MacCallum Cancer Centre-East Melbourne, East Melbourne, VIC, Australia.
  • Kichenadasse G; Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, VIC, Australia.
  • Zhang K; La Trobe University School of Cancer Medicine, Heidelberg, VIC, Australia.
  • Zhang M; Department of Medicine, University of Melbourne, Heidelberg, VIC, Australia.
  • Tang Z; Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, SA, Australia.
  • Millward M; BeiGene USA, Inc., San Mateo, CA, USA.
Br J Cancer ; 126(2): 310, 2022 Feb.
Article in En | MEDLINE | ID: mdl-34931042
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Language: En Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Language: En Year: 2022 Type: Article